Articles tagged "Co-stimulation"

2019 American Transplant Congress
Dual Treatment of CD40 Silencing or Mesenchymal Stem Cells Infusion with Sub-Therapeutic Doses of Cyclosporine Effectively Prevents Acute Rejection in an Allogenic Model of Renal Transplantation
J. Guiteras¹, L. De Ramon¹, N. Bolaños¹, M. Franquesa², M. Gomà³, J. Cruzado⁴, N. Lloberas¹, J. Grinyó⁴, J. Torras⁴
¹IDIBELL, Hospitalet de Llobregat, Spain, ²IGTP, Badalona, Spain, ³Bellvitge Hospital, Hospitalet de Llobregat, Spain, ⁴Bellvitge Hospital / IDIBELL, Hospitalet de Llobregat, Spain
*Purpose: This study was designed to investigate the combination of CD40 silencing or MSC infusion with suboptimal doses of Cyclosporine in this renal allograft model.*Methods:…
2019 American Transplant Congress
The Important Roles of Dendritic Cells in Transplantation
T. Ueno¹, M. M. McGrath¹, M. Y. Yeung¹, S. Cai¹, Y. Ueno¹, T. Yokoyama², Y. Kihara², O. Konno², Y. Nakamura², H. Iwamoto², A. K. Chandraker¹
¹Medicine, Renal Division, Brigham and Women's Hospital, Transplantation Research Center, Boston, MA, ²Kidney Transplantation Surgery, Tokyo Medical University, Hachioji Medical Center, Tokyo, Japan
*Purpose: The interplay between dendritic cells (DCs) and T cells plays a central role in the process of allograft rejection. Upon antigen exposure, positive costimulatory…
2019 American Transplant Congress
Belatacept Based CNI Free Immunosuppression in Pancreas Transplantation. Results at 4 Years
J. Chen, J. Fridell, M. Yaqub, T. Taber, D. MIshler, O. Adebiyi, M. Mujtaba, A. Sharfuddin
Indiana University School of Medicine, Indianapolis, IN
*Purpose: CNI based Immunosuppression is a well known risk factor for worsening renal function. We report our experience in converting Pancreas Transplant recipients from tacrolimus…
2019 American Transplant Congress
Regulatory T Cells Combined with Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts
B. Oh¹, G. Furtmüller¹, M. Grzelak¹, L. Vuong², M. Iglesias¹, M. Fryer³, D. Cooney¹, R. Chen⁴, Y. Guo⁵, W. Lee¹, G. Raimondi¹, G. Brandacher¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Washington University in St. Louis School of Medicine, St. Louis, MO, ³The University of Massachusetts Medical School, Worcester, MA, ⁴Kaohsiung Medical Univerity Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
*Purpose: Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…
2019 American Transplant Congress
Costimulatory Blockade and Allo-Specific Treg Therapy for Liver Transplant Recipients: Preclinical Data
L. Contreras-Ruiz¹, K. Shimozawa², R. Zhang¹, L. Turka³, J. F. Markmann³, E. C. Guinan²
¹Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, ²Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, ³Center of Transplantation Sciences, Massachussetts General Hosp., Boston, MA
*Purpose: Adoptive transfer of ex vivo generated donor-specific regulatory T cells (Treg) by using CD28/B7 costimulatory blockade (CSB) to induce transplant (TX) tolerance and minimize…
2019 American Transplant Congress
Impact Of Selective Cd28 Blockade On Protective Immunity To A Murine Epstein-Barr Virus Homolog
R. L. Crepeau, J. A. Elengickal, M. L. Ford
Surgery, Emory University, ATLANTA, GA
*Purpose: CTLA-4Ig blocks CD80/CD86, the ligands for both CD28 and CTLA-4. Thus, in addition to the intended effect of blocking CD28-mediated costimulation, CTLA4-Ig also has…
2019 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib Does Not Prevent DSA Formation and Rejection in Reconstructive Transplantation
F. Messner¹, Y. Guo¹, R. Chen², Y. Kuo², G. Brandacher¹, B. Oh¹
¹Department of Plastic and Reconstructive Surgery, Johns Hopkins UJohns Hopkins University School of Medicine, Baltimore, MD, ²Division of Plastic Surgery, Kaohsiung Medical Univerity Hospital, Kaohsiung, Taiwan
*Purpose: Sensitiziation in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection (AMR) constitute some of the greatest risk factors for allograft rejection and long-term…
2019 American Transplant Congress
B7H1 Expression is Crucial for Tolerance Induction in Mouse Liver Transplantation
M. Morita¹, S. Datta¹, C. Miller², T. Hamilton¹, K. Hashimoto³
¹Inflammation & Immunity, Lerner Research Institution, Cleveland, OH, ²General surgery, Liver Transplant Center, Cleveland Clinic, Cleveland, OH, ³General Surgery, Liver Transplant Center, Cleveland Clinic, Cleveland, OH
*Purpose: Following organ transplantation, lifelong immunosuppressive treatment is required and it causes severe side effects. Induction of donor specific tolerance is ideal, which actually spontaneously…
2019 American Transplant Congress
Interruption of Notch Signaling via Blockade of Delta-Like Ligands 1 and 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection
A. Matar, Y. Dong, B. Lovasik, D. Mathews, A. Ghosh, C. Breeden, A. Stephenson, W. Kitchens, A. Adams
Surgery and Transplantation, Emory University, Atlanta, GA
*Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy with the advent of belatacept, a novel CTLA4-Ig fusion protein that blocks CD28-mediated T…
2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…